ABSTRACT
Peripheral T-cell lymphomas (PTCLs) are aggressive hematologic malignancies that account for 10% to 15% of non-Hodgkin lymphomas. 1 Accurate and timely diagnosis is crucial for optimizing patient outcomes. Flow cytometry immunophenotyping (FCI) is a common laboratory technique used to detect absent, aberrant, and inappropriately increased or decreased T-cell antigen expression, all of which can be characteristic of PTCLs. 2 Aberrant immunophenotypes, however, are not entirely tumor specific and can shift over time. 3, 4 An important corollary study to FCI is T-cell clonality assessment. Nonneoplastic T-cell populations are polyclonal for T-cell receptor (TCR) gene rearrangements, whereas PTCLs are typically monoclonal. Evaluation of T-cell clonality by TCR profiling is, therefore, routinely used to confirm or refute a putative PTCL diagnosis and for the analysis of samples with equivocal morphologic or immunophenotypic findings.
The most common method for detecting T-cell clonality is via molecular TCR γ gene rearrangement analysis by polymerase chain reaction (TCR γ PCR). TCR γ PCR detects clonality in approximately 90% of PTCLs. 5, 6 The accuracy of this test is limited by the restricted diversity of TCR γ gene rearrangements, high levels of background noise amplification, and lack of clone quantification or immunophenotypic characterization. An alternative to TCR γ PCR is the flow cytometry-based IOTest Beta Mark TCR Vβ kit (Beckman Coulter). 7, 8 Most PTCLs comprise αβ T cells that express the TCR α and β chains. 9 The IOTest Beta Mark TCR Vβ kit is a panel of 24 antibodies that target the variable region of the TCR β chain and detect up to 70% of the T-cell repertoire. 7, 8 Using a threshold of 1.6 times the upper limit of normal, the kit has 89% sensitivity and 88% specificity for detecting PTCLs in peripheral blood. 10 Few clinical laboratories have adopted this assay due to its relatively high cost and complexity. Reagents for testing a single sample are expensive (approximately $125) and require assembly of eight separate tubes for flow cytometric analysis. Test interpretation is complicated and lacks reliable benchmarks. 10, 11 Thus, this assay is unlikely to replace TCR γ PCR any time soon.
Both PTCLs and normal peripheral blood comprise primarily T cells that express the TCR α and β chains. 9 The TCR β chain constant region is encoded by two genes, T-cell receptor β chain constant region 1 (TRBC1) and T-cell receptor β chain constant region 2 (TRBC2). 12, 13 Nonneoplastic T cells express a mixture of TRBC1 and TRBC2, whereas PTCLs are monoclonal for one β chain constant region variant. Recently, an antibody targeting TRBC1 was developed for use in chimeric antigen receptor T-cell therapy for T-cell lymphomas.
14 Preliminary flow cytometry studies with this antibody showed that TRBC1 expression is dramatically different in healthy peripheral blood samples and PTCLs, including four cases of T-cell large granular lymphocytic (T-LGL) leukemia and nine cases of adult T-cell leukemia/ lymphoma.
14 Here, we tested the performance of the TRBC1 antibody, along with antibodies to pan-T-cell markers and CD4 and CD8, as a clinical flow cytometry assay for T-cell clonality. We found that TRBC immunophenotyping is an accurate, precise, and simple method for detecting clonality in a diverse set of mature T-cell neoplasms.
Materials and Methods

Sample Selection
Approval for study of discarded clinical specimens was obtained through the Partners Institutional Review Board. Relevant demographic and diagnostic data were assembled through medical record review. Control samples were from 15 men and 24 women, who ranged in age from 21 to 89 years (median, 49 years), with normal range CBCs, including normal range WBC differential counts. Samples included in the study were collected prospectively from January to September 2018, from patients who had peripheral blood (51 samples) or bone marrow (two samples) submitted for diagnostic flow cytometric immunophenotyping for evaluation of possible involvement by a T-cell lymphoproliferative disorder. A subset of the patients had a history of a T-cell lymphoproliferative disorder.
Cell Staining and Flow Cytometry Immunophenotyping
Patient samples were analyzed by six-color or 10-color flow cytometric immunophenotypic analysis for the presence of a T-cell lymphoproliferative disorder. Patients with a history of cutaneous T-cell lymphoma were analyzed using a Sézary syndrome (SS) panel, which consisted of two six-color antibody cocktails (tube 1: CD2-APC, CD3-PerCP-Cy5.5, CD4-PE-Cy7, CD5-PE, CD7-FITC, and  CD8-APC-H7; tube 2: CD3-APC-H7, CD4-PerCP-Cy5.5,  CD7-FITC, CD25-APC, CD26 -PE, and CD52-PE-Cy7). All other patients were analyzed with two six-color antibody cocktails (tube 1: CD2-APC, CD3-PerCP-Cy5.5, CD4-PE-CY7, CD5-PE, CD7-FITC, and CD8-APC-H7; tube 2: CD3-PerCP-Cy5.5, CD8-APC-H7, CD16-FITC, CD56-PE-Cy7, CD57-FITC, and CD94-APC) or one 10-color antibody cocktail (tube 1: CD2-APC, CD3-BV421, CD4-PerCP-Cy5.5, CD5-PE-Cy7, CD7-BV605, CD8-V500, CD16-PE, CD45-APC-H7, CD56-APC-R700, and CD57-FITC) containing T-cell and T-LGL markers. In addition, for all cases studied, flow cytometric assessment for T-cell clonality employed a six-color antibody cocktail (CD3-PerCP-Cy5.5, CD4-PE-Cy7, CD5-APC, CD7-FITC, CD8-APC-H7, and TRBC1-PE; JOVI-1, Ansell). All other antibodies were obtained from Becton Dickinson. In total, 100-µL aliquots of peripheral blood or bone marrow were washed, incubated with antibody cocktails, and then treated with flow cytometric immunophenotyping (FACS) lysing solution, washed, and resuspended in deionized water prior to flow cytometric analysis. FCI was performed on a BD FACS Canto instrument (Becton Dickinson) and analyzed using FACS Diva Software (Becton Dickinson).
Flow cytometric findings (not including assessment for T-cell clonality) were analyzed in conjunction with history, consideration of all available laboratory findings, and morphologic findings. A case was considered positive for the presence of a T-cell lymphoproliferative disorder based, in part, on an aberrant pattern of staining for pan-T-cell markers (CD2, CD3, CD5, and CD7), CD4 and CD8, and T-LGL-associated markers (CD16, CD56, and CD57), as well as comparison with prior findings, if they were available. Cases were considered suspicious and not positive for a T-cell lymphoproliferative disorder in instances when there was an expanded population of CD3+, CD8+, CD57+ T-cell large granular lymphocytes (T-LGLs) (five cases) or other T-cell subsets (two cases) but without diagnostic morphologic and immunophenotypic features of a T-cell neoplasm.
Molecular TCR γ PCR
Gene rearrangement studies were performed using the BIOMED-2 kit (Invivoscribe) as previously described.
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Statistical Analyses
The Shapiro-Wilk test and maximum likelihood fitting of the Gaussian distribution were used for normality assessment. Precision was analyzed using analysis of variance. Exploratory data analysis was performed using statistical packages in the R programming language.
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Results
Assessment of the Normal Range of TRBC1 Expression in Nonneoplastic T Cells
Nonpathologic polyclonal T cells are known to express a mixture of TRBC1 and TRBC2. 12, 13 During the initial characterization of the TRBC1 antibody, a prior study showed that 25% to 47% of peripheral blood T cells express TRBC1. 14 The investigators observed that, on average, CD4+ cells express more TRBC1 than their CD8+ counterparts but did not quantify this difference. To further define the normal biologic range of TRBC1 expression, we performed flow cytometric immunophenotypic analysis to assess for T-cell clonality on 39 peripheral blood samples from healthy donors. Samples were selected based on CBCs and WBC differential counts that fell within normal limits. The resulting data set represented a group of individuals between the ages of 21 and 89 years (median, 49 years; interquartile range [IRQ], 36-63 years) who were 62% female.
Expression of TRBC1 in all healthy donor blood was polytypic ❚Figure 1A❚. The ratio of TRBC1+ to TRBC1-T cells was in the 1:1 to 1:2 range. Within the T-cell population, a mean (SD) of 44% (4.3%) of CD4+ cells and 39% (11%) of CD8+ cells expressed TRBC1. The distribution of TRBC1 expression in both compartments followed a Gaussian distribution, as confirmed by Q-Q plot analysis and ShapiroWilk testing ❚Figure 1B❚. A Gaussian model fitted to the CD4+ compartment (μ = 44 ± 0.68; σ = 4.2 ± 0.48) predicted the 95% confidence interval (CI) for TRBC1 expression to be 36% to 53% and the 99.7% CI to be 32% to 57%. A similar model for the CD8+ group (μ = 39 ± 1.7; σ = 11 ± 1.2) generated a 95% CI of 18% to 61% and a 99.7% CI of 7% to 71%. These CIs were used to assess the expression of TRBC1 in all subsequent experiments.
TRBC1 Expression in T-Cell Neoplasms
To evaluate the utility of TRBC immunophenotyping for diagnosing PTCLs, we tested 53 specimens that were submitted to the Brigham and Women's Hospital clinical flow cytometry laboratory for routine diagnostic workup for the presence of a possible T-cell lymphoproliferative disorder, including 51 peripheral blood samples and two bone marrow samples. A total of 36 specimens were diagnosed as positive for involvement by a PTCL based on clinical and laboratory findings, morphologic findings, and routine FCI (summarized in ❚Table 1❚). Cases typically exhibited aberrant expression of one or more T-cell markers (CD2, CD3, CD5, CD7) and/or an abnormal CD4/CD8 ratio. In addition, in cases considered positive for SS, there was an expanded population of CD7-, CD26-T cells (19 cases), and in cases considered positive for T-LGL leukemia, there was an expanded population of CD3+, CD8+, CD57+ T-LGL cells (seven cases). The remainder of the cases were considered negative for the presence of a PTCL based on assessment of clinical and laboratory findings, morphologic findings, and routine FCI. The baseline characteristics for these groups were very similar ❚Table 2❚.
The samples that were diagnosed as positive for involvement by a PTCL based on routine analysis underwent additional flow cytometric analysis to assess TRBC1 expression and had consistently restricted, monotypic TRBC1 expression. Large tumor clones were readily apparent on the flow cytometry plots in a variety of cases, including SS ❚Figure 2A❚ and ❚Figure 2B❚ and T-LGL leukemia ❚Figure 2C❚ and ❚Figure 2D❚. CD4+ or CD8+ T-cell clones were either TRBC1+ or TRBC1-, with excess TRBC1 corresponding to TRBC1 monoclonality and loss of TRBC1 corresponding to presumed TRBC2 monoclonality. Small tumor clones obscured by a polytypic T-cell background became evident after gating on the T cells that exhibited aberrant expression of CD4 or CD8 ❚Figure 3A❚ and ❚Figure 3B❚ or aberrant expression of one or more pan-T-cell markers ❚Figure 3C❚ and ❚Figure 3D❚. Samples that were considered negative for the presence of a PTCL, based on assessment of clinical and laboratory findings, morphologic findings, and routine FCI, underwent additional flow cytometric analysis to assess TRBC1 expression and did not exhibit monotypic TRBC1 expression.
As part of our analysis, we quantified TRBC1 expression in the appropriate CD4 and CD8 T-cell compartments of each test case. PTCL specimens had highly skewed TRBC1 expression levels ❚Figure 4A❚ and ❚Figure 4B❚. The median proportion of TRBC1 expression was 93% (IQR, 86%-97%) in TRBC1+ clones and 4% (IQR, 2%-12%) in TRBC1-clones, which were then inferred to be TRBC2+. In contrast, nonneoplastic specimens had a mixture of TRBC1+ and TRBC1-cells that were present in proportions previously seen for normal peripheral blood.
Using the 99.7% CD4 CI and the 95% CD8 CI as the normal ranges for TRBC1 expression, our flow cytometry clonality assay correctly categorized 94% of the test cases as either neoplastic or nonneoplastic. Moreover, clonality was appropriately detected in 97% of all PTCLs. One T-cell prolymphocytic leukemia was misinterpreted as polyclonal because the neoplastic cells accounted for 19% of T cells and did not exhibit an aberrant immunophenotype, so it was not possible to identify a subpopulation of neoplastic cells within the nonneoplastic population by immunophenotypic analysis to assess TRBC1 expression. In addition, two negative samples assessed for TRBC1 expression were miscategorized as monoclonal. Review of the flow cytometry plots revealed that these samples were likely insufficiently washed, making it difficult to separate out the TRBC1-and TRBC1+ cell populations, which confounded data analysis.
Overall, the TRBC1 antibody was accurate in distinguishing malignant PTCL samples from nonneoplastic controls. Using traditional flow cytometry as a gold standard, the sensitivity and specificity of the antibody for mature T-cell neoplasms were 97% (95% CI, 84%-100%) and 91% (95% CI, 71%-99%), respectively. A single false-negative result indicated the need for running the TRBC1 assay in the context of a broader diagnostic flow cytometry panel. The false positives emphasized the importance of adequate washing of cells following incubation with antibody for optimal assay performance.
Clonality Assessment With TRBC1 Flow Cytometry Is Comparable to Molecular TCR γ PCR and Resolves Confounding or Equivocal Diagnostic Cases
Of the 53 samples stained for TRBC1 expression, 34 were also submitted for molecular TCR γ PCR. The molecular assay correctly identified 24 samples as clonal and four samples as polyclonal ❚Table 3❚. Two nonneoplastic specimens were reported to be clonal in Vγ10, which is a nonspecific finding that can be present in a variety of nonneoplastic conditions. One SS sample was called polyclonal. Three other specimens, including two SS cases and one nonneoplastic control, were interpreted as oligoclonal and of uncertain significance. Based on the above, TCR γ PCR resolved clonality in 91% of samples with 96% sensitivity and 67% specificity.
In contrast, TRBC1 expression analysis appropriately classified 26 samples as clonal and five samples as polyclonal ❚Table 4❚. As previously mentioned, the associated false-negative and false-positive observations were attributable to the absence of relevant immunophenotyping markers from the abridged TRBC1 antibody panel and insufficient washing of the cells following incubation with the antibody cocktail. Interestingly, TRBC1 expression analysis successfully resolved T-cell clonality in the five samples with confounding TCR γ PCR results (Table  4 ). All three negative samples were correctly classified as polyclonal, and both SS samples were found to be monoclonal. Based on the above, TRBC1 immunophenotyping resolved clonality in 100% of samples with 96% sensitivity and 71% specificity.
An additional seven samples with equivocal routine flow cytometry results were submitted for TCR γ PCR and TRBC immunophenotyping ❚Table 5❚. This included five cases with an expanded population of CD3+, CD8+, CD57+ T-LGLs and two cases with a subpopulation of T cells with decreased CD7 and CD26, but without convincing overall immunophenotypic and morphologic features of involvement by a T-cell neoplasm. One specimen was polyclonal by both assays. The other six were oligoclonal by TCR γ PCR and of unclear clinical significance. Analysis of TRBC1 expression resolved two of these cases as monoclonal and four as polyclonal. One monoclonal case contained a subpopulation of cells with decreased expression of CD5 that exhibited restricted expression of TRBC1, and the second monoclonal case contained a subpopulation of cells with decreased expression of CD7 that exhibited restricted expression of TRBC1. Thus, a total of five TRBC1 polyclonal cases were identified. Medical record examination revealed that four of these patients were clinically negative for disease. One patient had active cutaneous T-cell lymphoma with unclear disease burden in the blood. Our TRBC1 clonality assay suggested that this patient's disease did not extend to the blood. Of the two cases that were monoclonal by TRBC1 immunophenotyping, one had a history of T-LGL and 
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❚Figure 4❚ T-cell receptor β chain constant region 1 (TRBC1) expression in CD4+ and CD8+ peripheral T-cell lymphomas (PTCLs) is highly skewed. Leukocytes from 17 nonneoplastic and 36 PTCL samples were immunostained for TRBC1, CD3, CD4, CD5, CD7, and CD8 and analyzed by flow cytometric immunophenotypic analysis. TRBC1 expression was measured in the appropriate CD4 or CD8 T-cell compartments, which were selected based on diagnostic information from the associated clinical flow cytometry immunophenotyping reports. Dot plot diagrams show the overall distribution of TRBC1 expression in CD4 (A) and CD8 (B) T-cell compartments for both nonneoplastic and neoplastic specimens, comprising CD4+ and CD8+ PTCLs. The 95% and 99.7% confidence intervals for the normal TRBC1 expression range are shown using dotted and solid horizontal lines, respectively.
the other had active lymphoplasmacytic lymphoma with concern for an accompanying T-cell neoplasm. In both cases, the clinicians chose not to pursue treatment of a possible T-cell malignancy because the pathology reports were equivocal. Availability of TRBC1 T-cell clonality data may have added clarity to these reports and helped guide appropriate therapy.
The TRBC1 Assay Is Consistent and Reliable
Precision is an important component of clinical assay validation. To establish the technical precision of TRBC immunophenotyping, we tested 10 normal peripheral blood samples in duplicate across two independent experiments. Five of the samples were run a third time. The intrarun repeatability in TRBC1 expression was 2.1 (repeatability limit [S l ] = 5.7), and the interrun repeatability was 1.9 (S l = 5.4; ❚Figure 5❚). In other words, the difference between replicate measurements was generally 2 to 5.5 units, indicating that the correlation between replicates was strong. The median signal-to-noise ratio was 22:1 (IQR, 13-41), which confirmed that the assay was very robust.
Next, we assessed the biologic variability of TRBC immunophenotyping. Specimens were collected from nine SS cases on multiple occasions over the course of 6 months ❚Table 6❚. Each sample was tested for T-cell clonality in an independent flow cytometry analysis. Two of the patients were found to have TRBC2+ (ie, non-TRBC1+) disease, whereas the remainder had TRBC1+ disease. Importantly, TRBC immunophenotyping was 100% concordant across all biologic replicates. The repeatability and repeatability limit of TRBC1 expression were 3.9 and 11, respectively, indicating that biologic variability was higher than technical noise. The greater variation in these data is not surprising and likely represents inherent fluctuations in disease burden or response to therapy.
Residual Neoplastic Clones Are Detectable by TRBC1 Monitoring
Clinical management of patients with cancer relies on the diagnostician's ability to monitor disease progression and evolution over time. A powerful T-cell clonality assay is expected to detect low levels of tumor burden. We designed a dilution study to explore the lower limit of detection in our assay ❚Figure 6❚. An SS specimen with aberrant CD7 loss was combined with control peripheral blood in 1:1, 1:10, and 1:100 dilutions. The undiluted specimen had 31% tumor cells in a total of 15,576 events.
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❚Figure 5❚ T-cell receptor β chain constant region 1 (TRBC1) immunoassay precision. Peripheral blood from 10 normal CBCs with differential analyses was stained for TRBC1, CD3, CD4, CD5, CD7, and CD8 and analyzed by flow cytometry immunophenotyping. Replicate TRBC1 expression measurements in the CD4 (A) and CD8 (B) T-cell compartments of individual samples tested in duplicate across two to three independent experiments. 6  97  TRBC1 monoclonal  6  95  TRBC1 monoclonal  6  87  TRBC1 monoclonal  6  97  TRBC1 monoclonal  7  79  TRBC1 monoclonal  7  85  TRBC1 monoclonal  8  79  TRBC1 monoclonal  8  81  TRBC1 monoclonal  9  63  TRBC1 monoclonal  9 67 TRBC1 monoclonal TRBC1, T-cell receptor β chain constant region 1; TRBC2, T-cell receptor β chain constant region 2. a Non-TRBC1 monoclonal.
The tumor represented 92% of the lymphocytes and 99% of the CD3+/CD5+ T cells, which were clearly monotypic for TRBC1. This clone remained detectable at the 1:1 and 1:10 dilutions, while the 1:100 dilution was interpreted as polyclonal. Thus, the lower limit of detection for the TRBC1 assay in this experiment was 3.1% tumor cells out of 37,256 total events. Although further studies are necessary to confirm the utility of the TRBC1 assay in samples with minimal residual disease, these findings are promising. Current flow cytometry panels designed for SS are poorly suited to detect low levels of disease. Incorporation of the TRBC1 antibody into these panels may significantly improve diagnostic accuracy.
Discussion
PTCLs typically express the TCR β chain, which has two constant region variants: TRBC1 and TRBC2. 9, 12, 13 Using an antibody targeting TRBC1, we validated TRBC immunophenotyping as an accurate, robust, and simple method for detecting T-cell clonality in peripheral blood specimens. We established the expression range for TRBC1 in normal T cells and demonstrated that mature PTCLs have highly skewed TRBC1 proportions. TRBC immunophenotyping of test cases submitted to the flow cytometry laboratory for routine diagnostic workup resulted in sample classification with 97% sensitivity and 91% specificity. Comparison with clonality assessment by TCR γ PCR revealed that the TRBC1 assay is comparable and possibly superior to molecular testing. TCR γ PCR was limited by poor specificity of Vγ10 amplification and lack of immunophenotypic clone characterization. In contrast, TRBC1 testing provided real-time information regarding T-cell clonality for immunophenotypically defined T-cell populations. Moreover, this assay was reliable, was precise, and had a broad detection range for tumor clones.
The limitations of the TRBC1 assay included sensitivity to immunostaining technique and antibody panel design. Not surprisingly, samples that were inadequately washed were difficult to interpret. Similarly, specimens with a small population of neoplastic T cells that did not exhibit aberrant expression of T-cell antigens were Leukocytes from an SS sample were diluted with control peripheral blood; immunostained for T-cell receptor β chain constant region 1 (TRBC1), CD3, CD4, CD5, CD7, and CD8; and analyzed by flow cytometry immunophenotyping (see text for details). TRBC1 expression was measured for the CD4 (green) and CD8 (red) T-cell compartments (A, undiluted; B, 1:1 dilution; C, 1:10 dilution; D, 1:100 dilution). CD7 expression was plotted in the corresponding CD4+ cells to demonstrate restricted TRBC1 expression in CD4+/CD7-T cells, which was detectable in samples diluted 1:1 and 1:10, but not 1:100, with normal peripheral blood.
also miscategorized as negative. Both of these hurdles are surmountable. Technical staff should adhere closely to immunostaining protocols and perform additional wash steps whenever cells appear to exhibit nonspecific staining. Flow cytometry panels to assess T-cell clonality based on TRBC1 expression should include all relevant T-cell antibody markers or other immunophenotypic markers that could serve to identify an aberrant or neoplastic T-cell population. With these caveats and modifications, we expect that the sensitivity and specificity of the TRBC1 assay for T-cell clonality in PTCLs will approach 100%. Another foreseen challenge is the possible irrelevance of TRBC immunophenotyping in the diagnosis of certain CD4-/CD8-/TRBC1-PTCLs and TRBC1-T-cell acute lymphoblastic leukemias (T-ALLs). Expression of the TCR β chain is a prerequisite for the TRBC1 T-cell clonality assay. A small proportion of normal T cells and T-cell neoplasms are γδ T cells or derived from γδ T cells and lack the TCR β chain. These cells are also typically negative for CD4 and CD8. Therefore, in its current form, the TRBC1 assay cannot distinguish between CD4-/ CD8-/TRBC1-PTCLs and normal γδ T cells. Moreover, approximately 50% of T-ALLs lack the TCR β chain. 18 Absence of TRBC1 in these tumor samples, therefore, cannot be interpreted as monoclonality for TRBC2, unless additional flow cytometric assessment demonstrates that the TCR β chain is expressed. Alternatively, the presence of restricted TRBC1 expression in possible T-ALL specimens can be interpreted as evidence of monoclonality. Development of pan-TRBC and TRBC2-specific antibodies will be a major step in optimizing TRBC-based T-cell clonality assessment.
Our study shows that TRBC immunophenotyping by flow cytometry is an accurate, precise, robust, and inexpensive method for evaluating T-cell clonality in peripheral blood and bone marrow in most PTCLs. Additional testing is needed to determine whether this approach will work with lymph node specimens and other tissue specimens; however, preliminary results indicate that neoplastic T-cell populations can be distinguished from nonneoplastic T-cells by TRBC immunophenotyping in lymph node specimens. In addition, further study is needed to determine whether TRBC1 staining in patients with a history of a T-cell lymphoproliferative disorder would be useful for the detection of minimal residual disease. The TRBC1 T-cell clonality assay is simple, rapid, and cost-effective. Data analysis is straightforward, and turnaround time is the same as for routine FCI. Moreover, the TRBC1 antibody can easily be added to standard flow cytometry panels for approximately $3/test and requires no more than one extra antibody cocktail tube for testing. As eight-color and 10-color multiparametric flow cytometric analysis becomes routine in clinical practice, it should be possible to add the TRBC1 antibody to flow cytometric panels to assess T-cell clonality as a component of clinical evaluation, similar to B-cell clonality assessment by surface immunoglobulin κ and λ light chain expression. We predict that integration of this technique into traditional diagnostic workflows will accelerate the availability of definitive diagnostic reports for T-cell lymphoproliferative disorders and lead to improved patient care. 
